Treatment for HER2-positive breast cancer involves targeted therapy using monoclonal antibodies, such as trastuzumab (Herceptin); which target the HER2 receptor and inhibit its associated pathways regulating proliferation, survival, migration and cell invasion [22]. This evidence concerns the gene ERBB2 and breast carcinoma.